Preanalytical considerations in the design of clinical trials and epidemiological studies

Clinical Chemistry

Volumn 61, Issue 6, 2015, Pages 797-803

  Kellogg, Mark D ^a   Ellervik, Christina ^a,b,c   Morrow, David ^a   Hsing, Ann ^d   Stein, Evan ^e   Sethi, Amar A ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NYKØBING FALSTER HOSPITAL   (Denmark)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Metabolic and Atherosclerosis Research Center ^*  (United States)

^f Pacific Biomarkers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; DNA; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEIC ACID; PROTEIN; SEX HORMONE;

AGE; BLOOD SAMPLING; BODY SIZE; CIRCADIAN RHYTHM; CLINICAL DECISION MAKING; CLINICAL LABORATORY; CLINICAL TRIAL (TOPIC); EPIDEMIOLOGY; GENETIC MARKER; HOSPITAL LABORATORY; HUMAN; LONGITUDINAL STUDY; MEDICAL HISTORY; RACE; REVIEW; SAMPLING; SEX; SOCIAL STATUS; STANDARDIZATION; STORAGE; STUDY DESIGN; THROMBOCYTE POOR PLASMA; CLINICAL CHEMISTRY; METHODOLOGY; STANDARDS;

BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; CLINICAL TRIALS AS TOPIC; EPIDEMIOLOGIC STUDIES; HUMANS; RESEARCH DESIGN;

EID: 84930515989     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.226118     Document Type: Review

References (0)